Triple Threat: EMA Endorses Three First-Time Biosimilars

CHMP Backs Rivals To Eylea/Aflibercept, Tysabri/Natalizumab And RoActemra/Tocilizumab

 
• By Dave Wallace

At an eventful European Medicines Agency committee meeting in July, three biosimilars from Biocon, Sandoz and Fresenius Kabi have become the first for each respective molecule – aflibercept, natalizumab and tocilizumab – to gain the endorsement of the CHMP.

Three Red London Buses
Three first-time biosimilar nods have come along at once • Source: Shutterstock

More from Biosimilars

More from Products